Complete response and Renal cell carcinoma in the Immunotherapy era: The paradox of good news
Renal cell carcinoma (RCC) is one of the most common urological cancers and the most frequent kidney solid tumor, being the clear cell RCC (ccRCC) the most frequent histological subtype (1). Survival outcomes of metastatic RCC (mRCC) have improved greatly during the last two decades with the advent of vascular endothelial growth factor-tyrosine kinase inhibitors (antiangiogenic agents, AA) and the incorporation of immune-checkpoint inhibitors (ICI) into the treatment landscape during the last 5 years (2,3).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Francisco Zambrana, Lucia Carril-Ajuria, Alfonso G ómez de Liaño, Nieves Martinez Chanza, Ray Manneh, Daniel Castellano, Guillermo de Velasco Tags: Hot Topic Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology